This article is more than 5 years old. Information may no longer be current.

Study assesses breast cancer subtype as risk stratification for reconstruction

Breast cancer subtyping during reconstruction allowed researchers to stratify patients by need for post-reconstruction radiation and recurrence-free survival.

Researchers assessed the utility of breast cancer subtyping during reconstruction in determining whether postmastectomy radiation therapy is necessary. The researchers also aimed to predict recurrence-free survival. Prospectively collected data from 1,931 reconstructed breasts from mastectomies conducted between November 1999 and December 2012 underwent analysis.

The data set was 39% luminal A, 27.9% luminal B, 11.6% luminal HER2, 7.4% HER2 enriched and 13.8% TNBC. Radiation was delivered in 48.3% of the HER2 enriched group, compared with 42% for luminal HER2, 37.2% for luminal B, 37.1% for TNBC and 29.5% for luminal A (P < .0001).

The survival outcome was better in luminal A patients compared with HER2 enriched patients. TNBC was associated with poorer recurrence-free survival than HER2 enriched. Luminal b and luminal HER2 cases yielded similar recurrence-free survival as HER2 enriched.

The strongest recurrence-free survival outcomes were reported for luminal A disease.

Disclosures: The researchers report no relevant financial disclosures.